MEDP - Breaking Update: Dani S Zander Engages In Options Exercise At Medpace Hldgs | Benzinga
Highlighted on July 3, it was unveiled in an SEC filing that Zander, Director at Medpace Hldgs (NASDAQ:MEDP), executed a significant transaction involving the exercise of company stock options.
What Happened: A notable Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission revealed that Zander, Director at Medpace Hldgs, exercised stock options for 0 shares of MEDP, resulting in a transaction value of $0.
Medpace Hldgs shares are trading, exhibiting down of 0.33% and priced at $403.07 during Thursday's morning. This values Zander's 0 shares at $0.
About Medpace Hldgs
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Financial Milestones: Medpace Hldgs's Journey
Positive Revenue Trend: Examining Medpace Hldgs's financials over 3 months reveals a positive narrative. The company ...